Physician profile
Xiaoyan Chen
NPI 1841490299
$658.64
in general payments reported to CMS, 2019-2025
11 companies · $61.48 in 2025
The $61.48 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $270 · 2020: $87.54 · 2023: $22.93 · 2024: $216 · 2025: $61.48.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $301.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $300.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $118.41 | 2019-2020 | |
| Pfizer INC. | $105.76 | 2019-2024 | |
| Abbvie INC. | $103.13 | 2023-2025 | Avycaz |
| Janssen Pharmaceuticals, INC | $68.38 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $57.28 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $53.70 | 2024 | Andexxa |
| Mallinckrodt Hospital Products INC. | $49.84 | 2024-2025 | Terlivaz |
| Eisai INC. | $47.99 | 2024 | |
| Portola Pharmaceuticals, LLC | $20.90 | 2019 | |
| Merck Sharp & Dohme LLC | $17.23 | 2019 | |
| Vifor Pharma, INC. | $16.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Xiaoyan Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.